Core Viewpoint - MIRXES-B has signed a memorandum of understanding with Crystal Technology to integrate genomic technology and a disease database focused on Asian populations with AI-driven drug discovery and research platforms, aiming to develop early detection and intervention solutions for prevalent cancers in Asia, particularly gastrointestinal cancers [1][2] Group 1 - The collaboration aligns with the long-term goal of promoting early detection and intervention to assist individuals in leading healthier lives [2] - This partnership signifies an important expansion from early detection to early intervention and precision medicine for the company [2] - The collaboration aims to create synergies by leveraging the complementary strengths of both companies, including high-quality cancer biomarker data and operational advantages in the Asia-Pacific region [2] Group 2 - Crystal Technology brings years of experience in AI research and development in biomedicine, along with capabilities in data collection, cleaning, and development in the biopharmaceutical sector [2] - The joint effort will focus on researching and industrializing AI-enabled innovative solutions for early diagnosis and treatment of high-incidence cancers in Asia [2]

格隆汇12月5日丨MIRXES-B(02629.HK)宣布，公司近期与晶泰控股有限公司订立了一份谅解备忘录， 据此，双方同意整合公司在基因组学技术及其庞大的、以亚洲人群为中心的疾病数据库方面的核心优 势，与晶泰科技领先的AI+机器人的药物发现和研究平台，针对亚洲高发癌种，特别是消化道癌的早期 发现与干预，共建一个AI赋能的、创新的「诊疗一体化」研究及产业化平台，结合诊断与治疗，合作 开发早诊早治解决方案。 ...

（股份代號：2629） 自願性公告 與晶泰科技的諒解備忘錄 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 諒解備忘錄 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） – 2 – 本公司董事（「董事」）會（「董事會」）宣佈，本公司近期與晶泰控股有限公司（「晶 泰科技」）訂立了一份諒解備忘錄（「諒解備忘錄」），據此，雙方同意整合本公司 在基因組學技術及其龐大的、以亞洲人群為中心的疾病數據庫方面的核心優勢， 與晶泰科技領先的AI+機器人的藥物發現和研究平台，針對亞洲高發癌種，特 別是消化道癌的早期發現與干預，共建一個AI賦能的、創新的「診療一體化」研 究及產業化平台，結合診斷與治療，合作開發 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02629 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | 0.00001 | USD | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存 ...

Core Viewpoint - Mirxes has signed a memorandum of understanding with Watson Bio to collaborate in molecular diagnostics and vaccine development, aiming to expand into ASEAN and global markets [1] Group 1: Company Developments - Mirxes' stock rose nearly 8% in early trading, currently up 2.48% at HKD 53.8, with a trading volume of HKD 18.2942 million [1] - The partnership with Watson Bio signifies a strategic collaboration between a leading precision diagnostics company and a top vaccine developer, establishing a solid foundation for an RNA-based preventive and precision medical platform [1] Group 2: Product Approval and Market Impact - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a commercial breakthrough for the company, transitioning from "0 to 1," and is expected to lead to a revaluation of the company's worth [1] - The approval allows Mirxes to enter the vast gastric cancer screening market in China, serving as a significant catalyst for short-term performance [1]

Core Insights - Mirxes-B (02629) experienced a nearly 8% increase in early trading, currently up 2.48% at 53.8 HKD with a trading volume of 18.29 million HKD [1] Company Developments - On November 18, Mirxes announced a formal memorandum of understanding with Watson Bio (300142.SZ) to collaborate in the fields of molecular diagnostics and vaccine development, aiming to expand in the ASEAN and global markets [1] - This partnership signifies a strategic alignment between a leading precision diagnostics company and a top vaccine development firm, laying a solid foundation for a prevention and precision medicine platform centered around RNA [1] Product Milestones - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and currently the only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a significant commercial breakthrough for the company, transitioning from "0 to 1," and introduces a new valuation logic for the firm [1] - The approval allows the company to officially enter the vast gastric cancer screening market in China, serving as a crucial catalyst for short-term performance [1]

Core Viewpoint - MIRXES-B has established a strategic partnership with Yunnan Watson Biotechnology to create an RNA-centered prevention and precision medicine platform, enhancing their capabilities in clinical trials, registration, and sales [1] Group 1: Partnership Details - The memorandum of understanding (MOU) between MIRXES and Watson is valid for two years from the signing date [1] - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1] Group 2: Technological and Operational Synergies - MIRXES will integrate its advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's mRNA vaccine technology [1] - The partnership will utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1] - The collaboration is expected to enhance both companies' research and commercial deployment capabilities in the field of prevention and precision medicine [1]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 5% in the afternoon trading session, with a current price of 52.55 HKD and a trading volume of 32.73 million HKD. The company has entered into a memorandum of understanding with Yunnan Watson Bio (300142) to establish a strategic partnership focused on RNA-based preventive and precision medicine [1]. Group 1 - The memorandum of understanding is set for a duration of two years from the date of signing [1]. - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1]. - The partnership will integrate MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and robust clinical pipeline [1]. Group 2 - The strategic partnership will encompass joint development, clinical trials, registration, as well as sales and distribution [1]. - The collaboration is expected to establish a comprehensive platform for research and commercial deployment in preventive and precision medicine [1]. - The partnership will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1].

Core Viewpoint - MIRXES-B (02629) has entered into a memorandum of understanding with Yunnan Watson Biotechnology to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to create synergies [1] Group 2: Technological and Operational Synergies - The partnership will combine MIRXES's advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's proprietary mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Objectives - The partnership will create synergies by combining MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]